Risk of Regional Recurrence After Negative Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence

AUTHOR GROUP

doi:https://doi.org/10.1245/s10434-018-6384-y

Risk of Regional Recurrence After Negative Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence

AUTHOR GROUP

Research output: Contribution to journal › Article › Academic › peer-review

15 Citations (Scopus)

Abstract

Repeat sentinel lymph node biopsy (rSLNB) has increasingly been used in patients with ipsilateral breast tumor recurrence (IBTR). The safety in terms of regional disease control after this procedure remains unclear. This study evaluates occurrence of regional recurrence as first event in patients with IBTR and negative rSLNB, treated without additional lymph node dissection. Data were obtained from the Sentinel Node and Recurrent Breast Cancer (SNARB) study. In 201 patients, tumor-negative rSLNB was obtained without performing additional lymph node dissections. 99mtechnetium) used during rSLNB were associated with developing regional recurrence as first event after negative rSLNB (P < 0.05). The risk of developing regional recurrence after negative rSLNB is low. The low relapse rate supports the safety of rSLNB as primary nodal staging tool in IBTR. The time has come for clinical guidelines to adopt rSLNB as axillary staging tool in patients with IBTR

Original language	English
Pages (from-to)	1312-1321
Journal	Annals of surgical oncology
Volume	25
Issue number	5
DOIs	https://doi.org/10.1245/s10434-018-6384-y
Publication status	Published - 2018

Access to Document

https://doi.org/10.1245/s10434-018-6384-y

Cite this

@article{0b82a1fb75fe474baba7eb7e02716183,

title = "Risk of Regional Recurrence After Negative Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence",

abstract = "Repeat sentinel lymph node biopsy (rSLNB) has increasingly been used in patients with ipsilateral breast tumor recurrence (IBTR). The safety in terms of regional disease control after this procedure remains unclear. This study evaluates occurrence of regional recurrence as first event in patients with IBTR and negative rSLNB, treated without additional lymph node dissection. Data were obtained from the Sentinel Node and Recurrent Breast Cancer (SNARB) study. In 201 patients, tumor-negative rSLNB was obtained without performing additional lymph node dissections. 99mtechnetium) used during rSLNB were associated with developing regional recurrence as first event after negative rSLNB (P < 0.05). The risk of developing regional recurrence after negative rSLNB is low. The low relapse rate supports the safety of rSLNB as primary nodal staging tool in IBTR. The time has come for clinical guidelines to adopt rSLNB as axillary staging tool in patients with IBTR",

author = "Poodt, {Ingrid G. M.} and Guusje Vugts and Maaskant-Braat, {Adriana J. G.} and Robert-Jan Schipper and Voogd, {Adri C.} and Nieuwenhuijzen, {Grard A. P.} and {AUTHOR GROUP} and Roumen, {R. M. H.} and Luiten, {E. J. T.} and Rutgers, {E. J. T.} and Vrancken-Peeters, {M. T. F. D.} and M. Bessems and Klaase, {J. M.} and S. Muller and Francken, {A. B.} and {van Dalen}, T. and L. Jansen and Koopal, {S. A.} and Vissers, {Y. L. J.} and Smidt, {M. L.} and Merkus, {J. W. S.} and Contant, {C. M. E.} and Veldman, {P. H.} and Linthorst-Niers, {E. M. H.} and {van der Sijp}, {J. R.} and Guicherit, {O. R.} and Koppert, {L. B.} and Bosch, {A. M.} and Strobbe, {L. J. A.} and Schlooz-Vries, {M. S.} and Arntz, {I. E.} and {van Essen}, {J. A.} and {de Waard}, {J. W. D.} and Vrouenraets, {B. C.} and {van Ooijen}, B.",

year = "2018",

doi = "https://doi.org/10.1245/s10434-018-6384-y",

language = "English",

volume = "25",

pages = "1312--1321",

journal = "Annals of surgical oncology",

issn = "1068-9265",

publisher = "Springer New York",

number = "5",

}

TY - JOUR

T1 - Risk of Regional Recurrence After Negative Repeat Sentinel Lymph Node Biopsy in Patients with Ipsilateral Breast Tumor Recurrence

AU - Poodt, Ingrid G. M.

AU - Vugts, Guusje

AU - Maaskant-Braat, Adriana J. G.

AU - Schipper, Robert-Jan

AU - Voogd, Adri C.

AU - Nieuwenhuijzen, Grard A. P.

AU - AUTHOR GROUP

AU - Roumen, R. M. H.

AU - Luiten, E. J. T.

AU - Rutgers, E. J. T.

AU - Vrancken-Peeters, M. T. F. D.

AU - Bessems, M.

AU - Klaase, J. M.

AU - Muller, S.

AU - Francken, A. B.

AU - van Dalen, T.

AU - Jansen, L.

AU - Koopal, S. A.

AU - Vissers, Y. L. J.

AU - Smidt, M. L.

AU - Merkus, J. W. S.

AU - Contant, C. M. E.

AU - Veldman, P. H.

AU - Linthorst-Niers, E. M. H.

AU - van der Sijp, J. R.

AU - Guicherit, O. R.

AU - Koppert, L. B.

AU - Bosch, A. M.

AU - Strobbe, L. J. A.

AU - Schlooz-Vries, M. S.

AU - Arntz, I. E.

AU - van Essen, J. A.

AU - de Waard, J. W. D.

AU - Vrouenraets, B. C.

AU - van Ooijen, B.

PY - 2018

Y1 - 2018

N2 - Repeat sentinel lymph node biopsy (rSLNB) has increasingly been used in patients with ipsilateral breast tumor recurrence (IBTR). The safety in terms of regional disease control after this procedure remains unclear. This study evaluates occurrence of regional recurrence as first event in patients with IBTR and negative rSLNB, treated without additional lymph node dissection. Data were obtained from the Sentinel Node and Recurrent Breast Cancer (SNARB) study. In 201 patients, tumor-negative rSLNB was obtained without performing additional lymph node dissections. 99mtechnetium) used during rSLNB were associated with developing regional recurrence as first event after negative rSLNB (P < 0.05). The risk of developing regional recurrence after negative rSLNB is low. The low relapse rate supports the safety of rSLNB as primary nodal staging tool in IBTR. The time has come for clinical guidelines to adopt rSLNB as axillary staging tool in patients with IBTR

AB - Repeat sentinel lymph node biopsy (rSLNB) has increasingly been used in patients with ipsilateral breast tumor recurrence (IBTR). The safety in terms of regional disease control after this procedure remains unclear. This study evaluates occurrence of regional recurrence as first event in patients with IBTR and negative rSLNB, treated without additional lymph node dissection. Data were obtained from the Sentinel Node and Recurrent Breast Cancer (SNARB) study. In 201 patients, tumor-negative rSLNB was obtained without performing additional lymph node dissections. 99mtechnetium) used during rSLNB were associated with developing regional recurrence as first event after negative rSLNB (P < 0.05). The risk of developing regional recurrence after negative rSLNB is low. The low relapse rate supports the safety of rSLNB as primary nodal staging tool in IBTR. The time has come for clinical guidelines to adopt rSLNB as axillary staging tool in patients with IBTR

U2 - https://doi.org/10.1245/s10434-018-6384-y

DO - https://doi.org/10.1245/s10434-018-6384-y

M3 - Article

C2 - 29497910

SN - 1068-9265

VL - 25

SP - 1312

EP - 1321

JO - Annals of surgical oncology

JF - Annals of surgical oncology

IS - 5

ER -